BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
ARMI | BioFabUSA will exhibit and present on NDIA 2025 biofabrication strategies at the Emerging Technologies for Defense Conference, August 27–29 in Washington, D.C. As a national leader in regenerative manufacturing, ARMI will highlight how tissue engineering and biomanufacturing innovations contribute to defense readiness and medical resilience.
Our exhibit will feature breakthrough technologies such as decellularized tissue scaffolds, engineered ligaments, and blood cell manufacturing platforms. These tools not only support warfighter recovery but also advance the Department of Defense’s strategic goals for innovation, supply chain resiliency, and battlefield care.
Attendees can learn how BioFabUSA’s work is driving new capabilities in:
BioFabUSA’s presentations will spotlight case studies and cross-sector collaborations that address critical gaps in defense health systems. We will also discuss how biomanufacturing innovations can bolster supply chain flexibility and response capabilities for both military and civilian medical applications.
This engagement reflects BioFabUSA’S s broader commitment to supporting national security through technology translation and advanced manufacturing.
BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.
